Bovine isolates of Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni, collected from 2000 to 2009, were tested for in vitro susceptibility to ceftiofur, penicillin, danofloxacin, enrofloxacin, florfenicol, tetracycline, tilmicosin, and tulathromycin. Ceftiofur remained very active against all isolates. Penicillin retained good activity against P. multocida and H. somni isolates with no appreciable changes in susceptibility or minimal inhibitory concentration (MIC) distributions with time. While there was no obvious trend, the percent of M. haemolytica that were susceptible to penicillin ranged from 40.9% to 66.7%. Danofloxacin MIC 50 and MIC 90 values for M. haemolytica and P. multocida did not change beyond a single dilution over the 6 years it was included in the testing panel. The MIC 90 for H. somni increased beyond 1 dilution. Enrofloxacin MIC 50 values for the 3 pathogens also did not change over time, unlike the MIC 90 values, which increased by at least 4-doubling dilutions. Ninety percent or more of M. haemolytica and H. somni isolates were susceptible to florfenicol, while susceptibility among P. multocida was 79% or greater. Less than 50% of the isolates tested as susceptible to tetracycline in many of the years. All 3 organisms showed declines in tilmicosin and tulathromycin MIC 50 and MIC 90 values over the years in which they were tested.
Introduction
Bovine respiratory disease (BRD) is a significant cause of morbidity and mortality among beef cattle in North America and elsewhere. The U.S. Department of Agriculture (USDA) survey of beef cattle operations in 1999 estimated that BRD was the most common cause of illness in U.S. feedlots, and 14.4% of cattle developed BRD after arrival at the feedlot (USDA: 2000, Feedlot '99. Part III: Health management and biosecurity in U.S. feedlots, 1999. Available at: http://www. aphis.usda.gov/animal_health/nahms/feedlot/downloads/ feedlot99/Feedlot99_dr_PartIII.pdf. Accessed on July 2, 2012) . In addition to animal welfare concerns, the economic impact of BRD is also substantial (USDA: 2000). 19, 20 Pasteurella multocida, Mannheimia haemolytica, and Histophilus somni have been identified as major bacterial etiologic agents for this disease complex. 6, 10 However, in spite of extensive study of cattle with BRD, there is still much that is not clear about the exact pathogenic role of these bacteria or the factors that contribute to development of disease. 21 Management of BRD includes the use of vaccines and antimicrobial drugs 7 and, in North America, there are a number of antimicrobial products that have approved labels for the treatment of this disease. At the beginning of the current study, the most recent data on antimicrobial usage on U.S. feedlots was the USDA Feedlot '99 study (USDA: 2000) . In that national survey, florfenicol was used most frequently (54%) by U.S. feedlots as part of the initial treatment of BRD, followed by tilmicosin, tetracyclines, cephalosporins, fluoroquinolones, and penicillins. Continued susceptibility of the BRD pathogens to these drugs was therefore important.
Exposure of bacteria to antimicrobial drugs has the potential to exert pressure for selection of resistant organisms and, in order to retain efficacy, veterinarians and producers are advised to practice good antimicrobial stewardship. The U.S. Food and Drug Administration (FDA), along with the American Veterinary Medical Association, have developed guidelines for beef cattle veterinarians on the judicious use of antimicrobial drugs (FDA: 2002: Judicious use of antimicrobials for beef cattle veterinarians. Available at: http:// www.fda.gov/downloads/AnimalVeterinary/SafetyHealth/ AntimicrobialResistance/JudiciousUseofAntimicrobials/ UCM095568.pdf. Accessed on July 2, 2012). Similar guidelines have been published in Canada. 3 As a component of good antimicrobial stewardship, antimicrobial susceptibility trends should be monitored over time (FDA: 2002) ; however, to the authors' knowledge, there have been no published, national surveys of the antimicrobial susceptibility of bovine respiratory disease pathogens most commonly found in North America since a 1988-1992 survey published in 1994. 25 The current report aims to fill the need for published data on the antimicrobial susceptibility of BRD pathogens in North America. The objective of the present study was to detect any changes of in vitro susceptibility among major BRD pathogens, isolated from pre-and postmortem bovine specimens across the United States and Canada, between 2000 and 2009.
Materials and methods

Participating laboratories
Twenty-four veterinary diagnostic laboratories across the United States and Canada participated in the surveillance program, although not all submitted isolates every year. Laboratories from the major beef cattle-producing areas of the United States and Canada are included in the program, and the regions from which isolates were obtained are shown in Table 1 .
Bacterial isolates
Mannheimia haemolytica, P. multocida, and H. somni were requested from veterinary diagnostic laboratories for this program. All bacteria had been isolated from diseased or deceased animals, although there was no information available on either the age or any recent antimicrobial treatment administered to the animals from which the bacteria were isolated. The isolates were selected by the laboratories, but the laboratories were requested not to use susceptibility as a criterion for submission. In order to limit overrepresentation from any one geographic area, the participating laboratories were asked to submit no more than a maximum number each year. While this number changed slightly during the 10-year period, the number was ≤40 isolates of each bacterial species per laboratory per year. Starting in 2003, Pfizer Animal Health (PAH) requested that participating laboratories send no more than 1 isolate of each bacterial species from a herd or ranch each quarter-year to reduce the risk of overrepresentation of clones from localized outbreaks. Isolates were 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009  Total   M. haemolytica  West  18  9  22  20  35  55  37  56  44  37  333  Plains  85  96  97  37  106  111  94  133  99  88  946  Midcentral  80  64  79  128  120  101  130  124  96  101  1,023  East  26  20  3  30  43  30  59  60  68  54  393  Canada  0  0  24  13  26  36  32  65  62  24  282  P. multocida  West  21  16  25  27  42  71  51  66  56  44  419  Plains  60  95  94  29  107  108  88  145  94  70  890  Midcentral  99  110  99  113  125  120  152  174  134  120  1,246  East  28  38  4  47  64  48  72  72  72  70  515  Canada  0  0  13  7  26  30  29  51  41  24  221  H. somni  West  2  8  10  17  14  27  16  27  25  21  167  Plains  38  81  59  49  55  62  63  79  67  60  613  Midcentral  35  34  64  90  92  97  126  76  74  57  745  East  2  6  0  16  20  17  25  26  30  26  168  Canada  0  0  4  8  20  32  24  28  25 identified to the genus and species level by the submitting laboratory before shipment to PAH. Standard biochemical tests and commercially available identification systems were used to confirm or further characterize the isolates when necessary. a,b
Minimal inhibitory concentration determinations
The use of multiple laboratories to conduct susceptibility testing can introduce bias into a surveillance study. 2, 12 Therefore, over the 10 years, all susceptibility testing was performed in only 2 laboratories (PAH, Kalamazoo, Michigan; Microbial Research Inc., Fort Collins, Colorado) to minimize potential testing bias. There was adherence to Clinical and Laboratory Standards Institute (CLSI) standardized methods in both laboratories, 5 as well as quality control during susceptibility testing ( Table 2 ). Minimal inhibitory concentrations (MICs) for all isolates were determined using a broth microdilution system. c At the beginning of the current study, in 2000, the custom 96-well microtiter panels included serial dilutions of the following antimicrobial agents: ceftiofur, enrofloxacin, florfenicol, penicillin, tetracycline, and tilmicosin. Two additional drugs, danofloxacin and tulathromycin, which are also indicated for the treatment of BRD, became available after the survey began and were added to the panel in 2004.
Concentration ranges for each antimicrobial agent were chosen to encompass appropriate quality control ranges and clinical breakpoints, wherever possible. In some years, the range of drug concentrations was altered or drugs were removed from the panel, as in 2004, when enrofloxacin was not included in order to accommodate additional antimicrobial agents in the 96-well microtiter plates. Direct colony suspensions were used when testing all organisms, and suspensions were prepared to yield a final concentration of bacteria of approximately 5 × 10 5 colony-forming units/ml. The CLSI-recommended quality control organisms were included with each day of testing ( Table 2) .
The CLSI has published veterinary-specific clinical breakpoints for ceftiofur, enrofloxacin, florfenicol, tetracycline, and tulathromycin and tentatively approved veterinary breakpoints for penicillin (Mark Papich, personal communication, 2011) for M. haemolytica, P. multocida, and H. somni, 5 and these are shown as bold vertical lines in Tables 3-5. The CLSI has established clinical breakpoints for tilmicosin in vitro activity against M. haemolytica, but not for P. multocida or H. somni. The drug sponsor has published a susceptible breakpoint for tilmicosin against P. multocida of ≤8 µg/ml, 18 which is the same tilmicosin breakpoint as has been published by CLSI for M. haemolytica. There are also CLSI-published breakpoints for susceptibility, but not resistance, for danofloxacin against M. haemolytica and P. multocida.
Results
Mannheimia haemolytica. The in vitro susceptibility of 2,977 M. haemolytica isolates was evaluated using CLSIapproved methods ( Table 3 ). There were no apparent changes in MIC distribution over time of the 2 β-lactams, penicillin and ceftiofur, tested against M. haemolytica. All M. haemolytica isolates demonstrated in vitro susceptibility (MIC ≤ 2 µg/ml) to ceftiofur over the 10 years of the survey. The percentage of isolates that had penicillin MIC values at or below the susceptible breakpoint (MIC ≤ 0.25 µg/ml) varied quite widely each year, but there was no clearly identifiable movement towards higher or lower MICs over this 10-year period.
There was a decline in the percentage of M. haemolytica isolates that were susceptible to danofloxacin ( Table 3 ).
The percentage of M. haemolytica isolates that were susceptible to the 2 macrolides, tilmicosin and tulathromycin, declined over time (Table 3 ). Tilmicosin and tulathromycin MICs showed appreciable shifts toward higher concentrations over the years they were tested in the current survey, and the MIC 90 values reflected these changes. Table 4 ). All of the P. multocida isolates demonstrated in vitro susceptibility to ceftiofur during the 10-year period.
Danofloxacin testing began in 2004 and, at that time, 88.2% of the P. multocida isolates were susceptible. Over the following 5 years, there was little change in the danofloxacin MIC 50 or MIC 90 (Table 4 ). In 2000, the enrofloxacin MIC 90 was ≤0.03 µg/ml, and all of the P. multocida isolates showed in vitro susceptibility to enrofloxacin; over the next 3 years, a few resistant isolates were observed (Table 4 ). In 2008, when enrofloxacin was included in the testing panel again, the MIC 90 values had increased to 0.5 µg/ml. In vitro susceptibility of the P. multocida isolates to florfenicol showed minor fluctuations during the 10-year period of the survey (Table 4 ). There was no discernible trend, either up or down, in the MIC 50 or MIC 90 for tetracycline between 2000 and 2009 although the proportion of isolates that were susceptible (MIC ≤ 2 µg/ml) declined.
There was a shift over time in the frequency distribution of tilmicosin MICs among the P. multocida isolates toward the higher MICs (Table 4) , and the percentage of isolates that were susceptible to tilmicosin, using the sponsor-proposed breakpoint of ≤8 µg/ml, decreased to 59.7% (percentage susceptible data not shown in Table 4 ). Ninety percent or more of P. multocida isolates were susceptible to tulathromycin over the 6 years that it was tested (Table 4) , and the MIC 90 increased 3 fold.
Histophilus somni. A total of 1,844 H. somni isolates were tested between 2000 and 2009. In vitro susceptibility to the β-lactams remained high, with no resistance to ceftiofur detected over the years, and more than 90% of isolates demonstrated susceptibility to penicillin ( (Table 5) , and the proportion of isolates that were susceptible (MIC ≤ 2 µg/ml) to this drug decreased. There was also a decrease over time in the proportion of H. somni isolates that were susceptible to tetracycline, with the MIC 50 increasing multiple dilutions to 4 µg/ml in 2009 (Table 5 ). Between 2000 and 2009, H. somni showed a shift in MICs distributions for the macrolides (Table 5) , with a decline over time in the proportion of isolates that have tilmicosin and tulathromycin MICs less than or equal to 16 µg/ml (Table 5 ).
Discussion
Given the welfare and economic concerns associated with 14-24% of North American cattle becoming sick or dying from BRD each year, 9, 20 it is of considerable importance that the etiological agents of BRD remain susceptible to the antimicrobial drugs that are used to treat this disease. It is surprising then that there are so few widespread studies that have been conducted in the United States or Canada that look for changes in the susceptibility of pathogens to these antimicrobial drugs over time. 24 = the number of isolates tested; %S = the percentage of isolates that are susceptible to the drug using Clinical and Laboratory Standards Institute (CLSI) criteria; -= no isolates with an MIC at that concentration; NA = not applicable because there are no veterinary-specific breakpoints approved by CLSI. % MIC frequency rows may not add to 100% due to rounding. Vertical lines indicate the CLSI approved breakpoints for susceptibility and resistance in Bovine Respiratory Disease pathogens. The unshaded areas show the range of drug concentrations used in the microtiter panel. Numbers in the lowest concentration of the tested range represent the percentage of isolates that had MICs less than or equal to the lowest drug concentration tested that year. Numbers above the highest concentration in the tested range represent the percentage of isolates that had MICs greater than the highest drug concentration tested that year. was not performed to determine coresistance patterns among the isolates from this 10-year study. As with any surveillance program, the present survey has its limitations and potential biases. The data in this program came from over 8,000 clinical bovine isolates and, while this is a substantial number, it is only a small representative sample of the BRD pathogen population in the United States and Canada.
A number of authors have highlighted the challenges of surveillance systems and the potential biases that may be encountered. 12, 15 As the isolates in the current study originated from many veterinary diagnostic laboratories, the methods of sample selection, collection, and submission varied among laboratories. The design of the survey, including limits on the number of isolates collected within a given time period from a single ranch or herd and from a single diagnostic laboratory, can help reduce, but not eliminate selection bias. The use of just 2 laboratories to perform the MIC testing minimized potential testing bias, and both laboratories adhered strictly to standard microbiological methods for susceptibility testing and quality control standards.
The current report provides an extensive survey of the antimicrobial susceptibility of major BRD pathogens isolated from cattle in the United States and Canada, during the years 2000-2009. The data shows that M. haemolytica, P. multocida, and H. somni exhibit in vitro resistance to some important antimicrobial drugs that are frequently used to treat this disease. In other instances, there was little change in the proportions of susceptible isolates or the MIC distributions with time. Continued surveillance of antimicrobial susceptibilities will remain an important tool for monitoring and evaluating interventions designed to ensure the efficacy of veterinary antimicrobial drugs.
